e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Inflammation and remodelling in lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
La simvastatina no inhibe la inflamación producida por las células pulmonares
Cecilia López Ramírez (Sevilla, Spain), Cecilia López Ramírez, Laura Carrasco Hernández, Elena Arellano Orden, Carmen Calero Acuña, Eduardo Márquez Martín, José Luis López Campos
Source:
International Congress 2015 – Inflammation and remodelling in lung disease
Session:
Inflammation and remodelling in lung disease
Session type:
Thematic Poster Session
Number:
3926
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Cecilia López Ramírez (Sevilla, Spain), Cecilia López Ramírez, Laura Carrasco Hernández, Elena Arellano Orden, Carmen Calero Acuña, Eduardo Márquez Martín, José Luis López Campos. La simvastatina no inhibe la inflamación producida por las células pulmonares. Eur Respir J 2015; 46: Suppl. 59, 3926
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Prevalencia y características de los pacientes con EPOC en la asistencia primaria de Latinoamérica
Source: Annual Congress 2013 –Sesión conjunta en castellano organizada por la SEPAR (España) y la ALAT (Latinamérica)
Year: 2013
Enfermedades pulmonares intersticiales relacionadas con el tabaco
Source: Annual Congress 2013 –Sesión conjunta en castellano organizada por la SEPAR (España) y la ALAT (Latinamérica)
Year: 2013
Cribado del cáncer de pulmón: nuevos avances
Source: International Congress 2014 – Session in Spanish "Sesión conjunta en castellano organizada por la ALAT (Asociación Latinoamericana de Tórax) y la SEPAR (Sociedad Española de Enfermedades Respiratorias)"
Year: 2014
Transplantation pulmonaire à l’heure de la médecine de précision Lung transplantation in the era of precision medicine
Source: International Congress 2019 – French programme 2019: Part II
Year: 2019
Où en est-on dans la prise en charge de la Covid en septembre 2021 ? / Management of COVID-19: where are we ?
Source: Virtual Congress 2021 – French programme 2021
Year: 2021
Exploration de la fonction respiratoire selon l'âge / Lung function testing and age
Source: Virtual Congress 2020 – French programme 2020: Part II
Year: 2020
Nuevos tratamientos para la fibrosis pulmonar
Source: Annual Congress 2013 –Sesión conjunta en castellano organizada por la SEPAR (España) y la ALAT (Latinamérica)
Year: 2013
Syndrome obésité-hypoventilation: de la physiologie au traitementObesity hypoventilation: from pathophysiology to treatment
Source: International Congress 2016 – ERS/French Programme I
Year: 2016
Exacerbation aiguë de la fibrose pulmonaire idiopathique: ce qu'il ne faut plus faire et ce qu'il reste à faire. / Acute exacerbation of idiopathic pulmonary fibrosis: what should not be done and what remains to be done?
Source: Virtual Congress 2021 – French programme 2021
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept